Modification of the pendant ring of podophyllotoxin David C. AyresChang Kee Lim Articles Pages: 99 - 101
Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors Brian F. IssellClaude TihonM. Elaine Curry Articles Pages: 113 - 115
Interaction of VP16-213 with the DNA repair antagonist chloroquine A. M. ArnoldJ. M. A. Whitehouse Articles Pages: 123 - 126
Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice Tina ColomboMassimo BrogginiMaurizio D'Incalci Articles Pages: 127 - 131
Pharmacokinetics of VP16-213 given by different administration methods M. D'IncalciP. FarinaF. Cavalli Articles Pages: 141 - 145
Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer William E. EvansJoseph A. SinkuleGaston Rivera Articles Pages: 147 - 150
Combination chemotherapy of the epipodophyllotoxin derivatives, Teniposide and Etoposide Larry M. AllenFrancisco TejadaStaffan Nordqvist Articles Pages: 151 - 156
A phase I trial of continuous infusion VP16-213 (Etoposide) Joseph AisnerDavid A. Van EchoPeter H. Wiernik Articles Pages: 157 - 160
Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia A. Thomas LookGary V. DahlAlvin M. Mauer Articles Pages: 161 - 167
VM26 therapy in children with drug-refractory lymphocytic leukemia Gaston RiveraGary V. DahlJ. V. Simone Articles Pages: 169 - 172
VM26 in malignant hematological diseases Umberto TirelliAntonino CarboneEligio Grigoletto Articles Pages: 173 - 174
Etoposide as a single agent in relapsed advanced lymphomas R. E. TaylorT. J. McElwainM. J. Peckham Articles Pages: 175 - 177
Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy P. G. HarperM. B. DallyR. L. Souhami Articles Pages: 179 - 180
Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy H. Cortés FunesP. DominguezC. Mendiola Articles Pages: 181 - 186
Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer Joseph AisnerMargaret WhitacrePeter H. Wiernik Articles Pages: 187 - 193
Vincristine, adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung F. E. von EybenÅ. ArwidiL. Tennvall Articles Pages: 195 - 197
Chemotherapy combination with cyclophosphamide (CTX) adriamycin (ADM), vincristine (VCR), and VP16-213 in small cell carcinoma of the lung (SCCL) J. M. GraciaA. Jimenez Articles Pages: 199 - 201
VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC) P. A. MadrigalG. P. MangaR. Garcia Gomez Articles Pages: 203 - 204
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC) Robert ChapmanLoretta ItriRobert Golbey Articles Pages: 205 - 207
VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma L. MorascaS. MarsoniR. Scapaticci Articles Pages: 209 - 210
The role of VP16-213 (Etoposide; NSC-141540) in gestational choriocarcinoma Edward S. NewlandsKenneth D. Bagshawe Articles Pages: 211 - 214
VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms J. MortimerR. M. BukowskiR. B. Livingston Articles Pages: 215 - 218
Reversal of recurrent laryngeal nerve palsy following VP16-213 combination therapy in a patient with metastatic teratoma of the testis Eileen D. Rubery Articles Pages: 219 - 221
Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma F. C. SchellH. Y. YapL. Esparza Articles Pages: 223 - 225
Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer G. Perez MangaP. L. Madrigal AlonsoH. Alburquerque Carbuccia Articles Pages: 227 - 229
Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen G. Perez MangaP. Madrigal AlonsoH. Alburquerque Carbuccia Articles Pages: 231 - 233